The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene
Open accessAbstract
Resveratrol (trans-3,5,4'-trihydroxystilbene) is a naturally occurring polyphenol with cancer chemopreventive properties in preclinical models of carcinogenesis, including those of colorectal cancer. Recently, a variety of analogues of resveratrol have been synthesised and investigated in in vitro assays. One analogue, 3,4,5,4'-tetramethoxystilbene (DMU 212), showed preferential growth-inhibitory and proapoptotic properties in transformed cells, when compared with their untransformed counterparts. As part of a chemoprevention drug development programme, the pharmacokinetic properties of DMU 212 were compared with those of resveratrol in the plasma, liver, kidney, lung, heart, brain and small intestinal and colonic mucosa of mice. DMU 212 or resveratrol (240 mg kg(-1)) were administered intragastrically, and drug concentrations were measured by HPLC. Metabolites were characterised by cochromatography with authentic reference compounds and were identified by mass spectrometry. The ratios of area of plasma or tissue concentration vs time curves of resveratrol over DMU 212 (AUC(res)/AUC(DMU212)) for the plasma, liver, small intestinal and colonic mucosa were 3.5, 5, 0.1 and 0.15, respectively. Thus, resveratrol afforded significantly higher levels than DMU 212 in the plasma and liver, while DMU 212 exhibited superior availability compared to resveratrol in the small intestine and colon. Resveratrol was metabolised to its sulphate or glucuronate conjugates, while DMU 212 underwent metabolic hydroxylation or single and double O-demethylation. DMU 212 and resveratrol inhibited the growth of human-derived colon cancer cells HCA-7 and HT-29 in vitro with IC(50) values of between 6 and 26 microM. In the light of the superior levels achieved in the gastrointestinal tract after the administration of DMU 212, when compared to resveratrol, the results provide a good rationale to evaluate DMU 212 as a colorectal cancer chemopreventive agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 3×
“Resveratrol has been reported to possess a variety of anti-inflammatory, antiplatelet and both pro- and antioestrogenic effects (Bertelli et al, 1996; Gehm et al, 1997; Jang et al, 1997; Uenobe et al, 1997).”
BackgroundYang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,253
Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00183-x · Cited by 1,620
Gehm, B. D., McAndrews, J. M., Chien, P.-Y., & Jameson, J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.14138 · Cited by 1,063
Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., & Dannenberg, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21875 · Cited by 786
Absorption of three wine-related polyphenols in three different matrices by healthy subjects
Goldberg, D. M., Yan, J., & Soleas, G. J. (2003) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00397-1 · Cited by 683
Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., & Ducharme, M. P. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033340 · Cited by 480
Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002) · PubMed · Cited by 423
Antineoplastic Agents. 291. Isolation and Synthesis of Combretastatins A-4, A-5, and A-6
Pettit, G. R., Singh, S. B., Boyd, M. R., Hamel, E., Pettit, R. K., Schmidt, J. M., & Hogan, F. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00010a011 · Cited by 396
Inhibition of cancer growth by resveratrol is related to its low bioavailability
Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., & Estrela, J. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00911-5 · Cited by 388 · cited 1×
“This notion is borne out by studies in mice, rats and dogs, which suggest consistently that resveratrol is well absorbed but avidly glucuronidated and sulphated both in the liver and in intestinal epithelial cells (Asensi et al, 2002;Juan et al, 2002; Marier et al, 2002).”
BackgroundA reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol
Gusman, J. (2001) · Carcinogenesis · doi:10.1093/carcin/22.8.1111 · Cited by 388
Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600197 · Cited by 380
Self-citationSchneider, Y., Vincent, F., Duranton, B., Badolo, L., Gossé, F., Bergmann, C., Seiler, N., & Raul, F. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00511-5 · Cited by 341
Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.
Bhat, K., Lantvit, D. D., Christov, K. T., Mehta, R. G., Moon, R. C., & Pezzuto, J. M. (2001) · PubMed · Cited by 330
Human, Rat, and Mouse Metabolism of Resveratrol
Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., & van Breemen, R. B. (2002) · Pharmaceutical Research · doi:10.1023/a:1021414129280 · Cited by 319
Tessitore, L., Davit, A., Sarotto, I., & Caderni, G. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.619 · Cited by 282
Vitrac, X., Desmoulière, A., Brouillaud, B., Krisa, S., Deffieux, G., Barthe, N., Rosenbaum, J., & Mérillon, J.-M. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00096-1 · Cited by 280
Resveratrol Is Absorbed in the Small Intestine as Resveratrol Glucuronide
Kuhnle, G., Spencer, J. P. E., Chowrimootoo, G., Schroeter, H., Debnam, E. S., Srai, S. K. S., Rice-Evans, C., & Hahn, U. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2750 · Cited by 249
Sgambato, A., Ardito, R., Faraglia, B., Boninsegna, A., Wolf, F. I., & Cittadini, A. (2001) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(01)00232-7 · Cited by 244
Resveratrol Is a Selective Human Cytochrome P450 1A1 Inhibitor
Chun, Y. J., Kim, M. Y., & Guengerich, F. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1152 · Cited by 243
The Mucosa of the Small Intestine: How Clinically Relevant as an Organ of Drug Metabolism?
Doherty, M. M., & Charman, W. N. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00001 · Cited by 239
Wolter, F., Akoglu, B., Clausnitzer, A., & Stein, J. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.8.2197 · Cited by 236
Schneider, Y., Duranton, B., Goss, F., Schleiffer, R., Seiler, N., & Raul, F. (2001) · Nutrition and Cancer · doi:10.1207/s15327914nc391_14 · Cited by 202
Mutoh, M. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.959 · Cited by 190
Li, Z. G. (2002) · Carcinogenesis · doi:10.1093/carcin/23.9.1531 · Cited by 169
Kim, S., Ko, H., Park, J. E., Jung, S., Lee, S. K., & Chun, Y.-J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010298j · Cited by 168
Mahyar-Roemer, M., Katsen, A., Mestres, P., & Roemer, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1516 · Cited by 163
Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies
Peter Guengerich, F., Chun, Y.-J., Kim, D., Gillam, E. M. J., & Shimada, T. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(02)00333-0 · Cited by 163
Shimada, T., Sugie, A., Shindo, M., Nakajima, T., Azuma, E., HASHIMOTO, M., & Inoue, K. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(02)00035-2 · Cited by 157
Antimutagenic effect of resveratrol against Trp-P-1
Uenobe, F., Nakamura, S., & Miyazawa, M. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(96)00191-1 · Cited by 153
Chun, Y., Kim, S., Kim, D., Lee, S. K., & Guengerich, F. P. (2001) · PubMed · Cited by 148
Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver
Santi, C. D., Pietrabissa, A., Mosca, F., & Pacifici, G. M. (2000) · Xenobiotica · doi:10.1080/00498250010002487 · Cited by 131
Absorption of trans-resveratrol in rats
Soleas, G. J., Angelini, M., Grass, L., Diamandis, E. P., & Goldberg, D. M. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)35239-4 · Cited by 125
Bertelli, A. A. E., Giovannini, L., Stradi, R., Urien, S., Tillement, J. P., & Bertelli, A. A. A. (1996) · PubMed · Cited by 120
Inhibition of protein kinase C by resveratrol
Slater, S. J., Seiz, J. L., Cook, A. C., Stagliano, B. A., & Buzas, C. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00214-4 · Cited by 113
Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells
Mahyar-Roemer, M., Köhler, H., & Roemer, K. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-27 · Cited by 100
Lu, J., Ho, C., Ghai, G. R., & Chen, K. Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.2.321 · Cited by 98
Dopamine sulphate: an enigma resolved.
Eisenhofer, G., Coughtrie, M. W. H., & Goldstein, D. S. (1999) · PubMed · Cited by 93
Plasmatic levels of trans-resveratrol in rats
Juan, M. E., Buenafuente, J., Casals, I., & Planas, J. M. (2002) · Food Research International · doi:10.1016/s0963-9969(01)00183-1 · Cited by 86
She, Q., Ma, W., Wang, M., Kaji, A., Ho, C., & Dong, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206370 · Cited by 57
Cited by
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Bioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051
Potential Adverse Effects of Resveratrol: A Literature Review
Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W. M., Eid, A. H., Nasrallah, G. K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062084 · Cited by 716
“For instance, RE plasma peak concentrations of 32 μM were reported in rodents [47,48].”
BackgroundMetabolism and bioavailability oftrans-resveratrol
Wenzel, E., & Somoza, V. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500010 · Cited by 676
Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients
Patel, K. R., Brown, V. A., Jones, D. J. L., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2027 · Cited by 624
Self-citation
Metadata
- Authors
- Sale, S., Verschoyle, R. D., Boocock, D., Jones, D. J. L., Wilsher, N., Ruparelia, K. C., Potter, G. A., Farmer, P. B., Steward, W. P., & Gescher, A. J.
- Venue
- British Journal of Cancer
- Published
- 2004-02
- Volume
- 90
- Issue
- 3
- Pages
- 736-744
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2077764145
- Cited by
- 260
- References
- 40
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.